Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus

GlobeNewsWire • Jun 2, 2026

Top 3 Health Care Stocks You'll Regret Missing In May

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga • May 26, 2026

Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 12, 2026

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

GlobeNewsWire • May 6, 2026

Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market

Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets broader serotype coverage than competitors and is in pivotal Phase 3 adult and Phase 2 infant trials. PCVX boasts strong financials, with over $2.4B in cash and a completed manufacturing facility, enabling concurrent late-stage development and commercial preparation.

Seeking Alpha • May 2, 2026

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT.

GlobeNewsWire • Apr 7, 2026

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive® (PCV21) and Prevnar 20® (PCV20), the Current Standard-of-Care PCVs

GlobeNewsWire • Mar 23, 2026

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026

GlobeNewsWire • Mar 18, 2026

Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript

Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 25, 2026

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Expected Either Sequentially or Together by End of First Half of 2027 Company Advancing Early-Stage Pipeline, Expects to Initiate Phase 1 Adult Clinical Study for VAX-A1, a Vaccine Candidate to Prevent Group A Strep, in 2026 Company Advances Global and U.S. Manufacturing Capabilities to Support Commercialization of Pneumococcal Conjugate Vaccines with Completion of Dedicated Lonza Facility and Initiation of North Carolina Fill-Finish Line Buildout Approximately $2.4 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 ; Excludes Approximately $600.2 Million in Net Proceeds from February 2026 Equity Offering Company to Host Webcast/Conference Call Today at 4:30 p.m. ET / 1:30 p.m.

GlobeNewsWire • Feb 24, 2026